All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Carla Casulo of the Wilmont Cancer Institute and colleagues completed a multicenter study comparing outcomes in follicular lymphoma (FL) patients with early treatment failure after frontline rituximab-based chemotherapy, who received autologous stem cell transplant (SCT) and those who did not. The study findings were published online on December 11, 2017, in Biology of Blood and Marrow Transplantation.
An earlier study by Casulo showed that patients with FL who have disease progression or do not achieve a partial response, within the first 2 years after treatment have a much worse survival prognosis. The goal of this study was to determine if high dose chemotherapy with autologous SCT will improve overall survival (OS) in patients who have early treatment failure.
The results of this study advocate consideration of autologous SCT for FL patients who have early treatment failure, following frontline rituximab-based chemotherapy. The analysis of SCT within the first year after treatment failure supports a survival advantage in this cohort of patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox